Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

AimsWe investigated whether the insertion/deletion (I/D) polymorphism of the ACE gene modified the adherence to ACE inhibitors as measured by the discontinuation of an ACE inhibitor, or addition of another antihypertensive drug.MethodsThis was a cohort study among 239 subjects who started ACE inhibitor therapy. A Cox proportional hazard model was used to calculate relative risk (RR).ResultsDuring follow-up there was no significant difference between subjects with the DD, ID or II genotype (DD vs II; RR = 1.17, 95%CI: 0.78, 1.77 and ID vs II; RR = 1.06, 95%CI: 0.73, 1.55) in adherence.ConclusionsThe I/D polymorphism of the ACE gene does not influence the adherence to ACE inhibitors.

More information Original publication

DOI

10.1111/j.1365-2125.2004.02332.x

Type

Journal article

Publication Date

2005-04-01T00:00:00+00:00

Volume

59

Pages

483 - 485

Total pages

2

Addresses

D, e, p, a, r, t, m, e, n, t, , o, f, , E, p, i, d, e, m, i, o, l, o, g, y, , &, , B, i, o, s, t, a, t, i, s, t, i, c, s, ,, , E, r, a, s, m, u, s, , M, C, ,, , R, o, t, t, e, r, d, a, m, ,, , T, h, e, , N, e, t, h, e, r, l, a, n, d, s, .

Keywords

Humans, Hypertension, DNA Transposable Elements, Antihypertensive Agents, Angiotensin-Converting Enzyme Inhibitors, Analysis of Variance, Risk Assessment, Cohort Studies, Prospective Studies, Polymerase Chain Reaction, Patient Compliance, Gene Deletion, Genotype, Polymorphism, Genetic, Aged, Middle Aged